The association between B-cell non-Hodgkin lymphoma (NHL) and hepatitis B virus (HBV) is well demonstrated by epidemiological studies. Most studies concerning this association have been conducted in endemic areas. Thus, little is known concerning the clinical characteristics of HBV-related lymphomas in non-endemic areas. Here, we report the characteristics and outcomes of 39 patients with active HBV infection and B-cell NHL collected retrospectively in France and Italy. We also compared their characteristics with those of HCV-positive patients with NHL. The gender ratio (M/F) was 3.3 and the median age at NHL diagnosis, 59 years. The pathological distribution was 24 (62%) diffuse large B-cell lymphomas (DLBCLs) and 15 (38%) other lymphomas subtypes: marginal zone lymphoma (n = 6), follicular lymphoma (n = 3), mantle cell lymphoma (n = 2), Burkitt's lymphoma (n = 1), and not otherwise specified low-grade B-NHL (n = 3). Treatment included antiviral therapy for 35 patients (90%). Twenty-two (92%) DLBCL patients received an R-CHOP or R-CHOP-like regimen, leading to complete remission for 18 (75%).At one year, 21 DLBCL patients (88%) were alive, and 13 other B-cell lymphoma patients (87%) were alive. This European study underscores the predominance of DLBCL among patients with active HBV infection and their similar outcomes to non-HBV infected patients with DLBCL when treated with R-CHOP and antivirals.

中文翻译：

---

西欧非疫区的乙型肝炎病毒相关的B细胞非霍奇金淋巴瘤：临床特征和预后。

流行病学研究充分证明了B细胞非霍奇金淋巴瘤（NHL）与乙型肝炎病毒（HBV）之间的关联。关于这种关联的大多数研究都是在流行地区进行的。因此，关于在非流行地区的HBV相关淋巴瘤的临床特征知之甚少。在这里，我们报告了法国和意大利回顾性收集的39例活动性HBV感染和B细胞NHL患者的特征和结局。我们还将他们的特征与NHL的HCV阳性患者的特征进行了比较。性别比（M / F）为3.3，在NHL诊断时的平均年龄为59岁。病理分布为24（62％）弥漫性大B细胞淋巴瘤（DLBCL）和15（38％）其他亚型：边缘区淋巴瘤（n = 6），滤泡性淋巴瘤（n = 3），套细胞淋巴瘤（n = 2），伯基特氏淋巴瘤（n = 1），未另行指定低度B-NHL（n = 3）。治疗包括针对35例患者（90％）的抗病毒治疗。22名（92％）DLBCL患者接受了R-CHOP或R-CHOP样治疗，导致18名患者（75％）完全缓解。一年后，有21名DLBCL患者还活着（88％），其他13名B细胞淋巴瘤患者（87％）还活着。这项欧洲研究强调了在接受活动性HBV感染的患者中DLBCL的优势，以及与非HBV感染的DLBCL患者进行R-CHOP和抗病毒药物治疗后的结局相似。21例DLBCL患者（88％）还活着，其他13例B细胞淋巴瘤患者（87％）还活着。这项欧洲研究强调了在接受活动性HBV感染的患者中DLBCL的优势，以及与非HBV感染的DLBCL患者进行R-CHOP和抗病毒药物治疗后的结局相似。21例DLBCL患者（88％）还活着，其他13例B细胞淋巴瘤患者（87％）还活着。这项欧洲研究强调了在接受活动性HBV感染的患者中DLBCL的优势，以及与非HBV感染的DLBCL患者进行R-CHOP和抗病毒药物治疗后的结局相似。